268 related articles for article (PubMed ID: 27739361)
41. Mitochondrial-targeted penetrating peptide delivery for cancer therapy.
Wu J; Li J; Wang H; Liu CB
Expert Opin Drug Deliv; 2018 Oct; 15(10):951-964. PubMed ID: 30173542
[TBL] [Abstract][Full Text] [Related]
42. Niclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities.
Barbosa EJ; Löbenberg R; de Araujo GLB; Bou-Chacra NA
Eur J Pharm Biopharm; 2019 Aug; 141():58-69. PubMed ID: 31078739
[TBL] [Abstract][Full Text] [Related]
43. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery.
Wu M; Fan Y; Lv S; Xiao B; Ye M; Zhu X
Drug Deliv; 2016 Oct; 23(8):2720-2725. PubMed ID: 26203691
[TBL] [Abstract][Full Text] [Related]
44. Nanomaterial-induced autophagy: a new reversal MDR tool in cancer therapy?
Panzarini E; Dini L
Mol Pharm; 2014 Aug; 11(8):2527-38. PubMed ID: 24921216
[TBL] [Abstract][Full Text] [Related]
45. Nanomedicine-driven molecular targeting, drug delivery, and therapeutic approaches to cancer chemoresistance.
Khot VM; Salunkhe AB; Pricl S; Bauer J; Thorat ND; Townley H
Drug Discov Today; 2021 Mar; 26(3):724-739. PubMed ID: 33359624
[TBL] [Abstract][Full Text] [Related]
46. Hierarchical targeted hepatocyte mitochondrial multifunctional chitosan nanoparticles for anticancer drug delivery.
Chen Z; Zhang L; Song Y; He J; Wu L; Zhao C; Xiao Y; Li W; Cai B; Cheng H; Li W
Biomaterials; 2015 Jun; 52():240-50. PubMed ID: 25818430
[TBL] [Abstract][Full Text] [Related]
47. [Nanoparticles in diagnostics and therapy: towards nanomedicine].
Rotomskis R; Streckyte G; Karabanovas V
Medicina (Kaunas); 2006; 42(7):542-58. PubMed ID: 16861836
[TBL] [Abstract][Full Text] [Related]
48. Drug delivery/imaging multifunctionality of mesoporous silica-based composite nanostructures.
Chen Y; Chen H; Shi J
Expert Opin Drug Deliv; 2014 Jun; 11(6):917-30. PubMed ID: 24746014
[TBL] [Abstract][Full Text] [Related]
49. Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs.
Huang W; Chen L; Kang L; Jin M; Sun P; Xin X; Gao Z; Bae YH
Adv Drug Deliv Rev; 2017 Jun; 115():82-97. PubMed ID: 28624478
[TBL] [Abstract][Full Text] [Related]
50. Nanomaterials multifunctional behavior for enlightened cancer therapeutics.
Raju GSR; Dariya B; Mungamuri SK; Chalikonda G; Kang SM; Khan IN; Sushma PS; Nagaraju GP; Pavitra E; Han YK
Semin Cancer Biol; 2021 Feb; 69():178-189. PubMed ID: 31419527
[TBL] [Abstract][Full Text] [Related]
51. Programmable nanomedicine: synergistic and sequential drug delivery systems.
Pacardo DB; Ligler FS; Gu Z
Nanoscale; 2015 Feb; 7(8):3381-91. PubMed ID: 25631684
[TBL] [Abstract][Full Text] [Related]
52. Oral delivery of anticancer drugs I: general considerations.
Mazzaferro S; Bouchemal K; Ponchel G
Drug Discov Today; 2013 Jan; 18(1-2):25-34. PubMed ID: 22951365
[TBL] [Abstract][Full Text] [Related]
53. Recent Findings on Nanotechnology-based Therapeutic Strategies Against Hepatocellular Carcinoma.
Samie HAA; Saeed M; Faisal SM; Kausar MA; Kamal MA
Curr Drug Metab; 2019; 20(4):283-291. PubMed ID: 30854953
[TBL] [Abstract][Full Text] [Related]
54. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
55. Curcumin-guided nanotherapy: a lipid-based nanomedicine for targeted drug delivery in breast cancer therapy.
Lin M; Teng L; Wang Y; Zhang J; Sun X
Drug Deliv; 2016 May; 23(4):1420-5. PubMed ID: 26203688
[TBL] [Abstract][Full Text] [Related]
56. Stimuli-responsive polymeric micelles for drug delivery and cancer therapy.
Zhou Q; Zhang L; Yang T; Wu H
Int J Nanomedicine; 2018; 13():2921-2942. PubMed ID: 29849457
[TBL] [Abstract][Full Text] [Related]
57. Oral delivery of anticancer drugs III: formulation using drug delivery systems.
Mazzaferro S; Bouchemal K; Ponchel G
Drug Discov Today; 2013 Jan; 18(1-2):99-104. PubMed ID: 22981667
[TBL] [Abstract][Full Text] [Related]
58. Cancer drug delivery: considerations in the rational design of nanosized bioconjugates.
Kobayashi H; Turkbey B; Watanabe R; Choyke PL
Bioconjug Chem; 2014 Dec; 25(12):2093-100. PubMed ID: 25385142
[TBL] [Abstract][Full Text] [Related]
59. [Target selectivity of anticancer drugs].
Fattoruso SI; Di Lauro L; Conti F; Amodio A; Lopez M
Clin Ter; 2008; 159(3):189-206. PubMed ID: 18594750
[TBL] [Abstract][Full Text] [Related]
60. Subcellular drug distribution: mechanisms and roles in drug efficacy, toxicity, resistance, and targeted delivery.
Li Q; Zhou T; Wu F; Li N; Wang R; Zhao Q; Ma YM; Zhang JQ; Ma BL
Drug Metab Rev; 2018 Nov; 50(4):430-447. PubMed ID: 30270675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
